IGF-1 normalization was achieved in 35% of pure GH-PAs cases and in 50% of GH&PRL-PA patients (cabergoline dose ranging between 1.0 and 1.75 mg/week), where responding patients tended to have lower baseline IGF-1 (44). This evidence concerns the gene GH1 and gonorrhea.